SecBot SecBot
Biotech Drug Report Generated Aug 24, 2026

Apretude

GSK·GSK plc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercialized (FDA approved December 2021)
Why 3/10
Apretude is already FDA-approved and commercialized with no pending PDUFA or pivotal readout in the next ~12 months. It is one of many products in a large, diversified pharma company (GSK), so even strong sales growth or competitive news for this single drug would drive only a modest move in GSK's share price. Per the rubric, an approved drug with no imminent binary catalyst scores 3-5; 3 is appropriate given low concentration relative to GSK's total pipeline.
Actionable Insight NEUTRAL

Apretude is a commercial-stage asset with no near-term binary regulatory catalyst. Watch for quarterly ViiV sales disclosures within GSK's earnings, competitive threat from Gilead's evolving long-acting PrEP pipeline (e.g., lenacapavir), and any label-expansion updates. For GSK investors, Apretude is a growth contributor but not a standalone thesis driver.

Price Chart

Loading chart...

Executive Summary

Apretude (cabotegravir extended-release injectable) is the first and only long-acting injectable option for HIV pre-exposure prophylaxis (PrEP), developed by ViiV Healthcare (majority-owned by GSK). FDA-approved in December 2021, it offers every-2-month dosing vs. daily oral pills like Truvada/Descovy. Real-world data shows >99% effectiveness and zero HIV acquisitions in implementation studies. However, as an already-approved, marketed product within a large diversified pharma company, there is no imminent binary catalyst to move GSK's stock meaningfully on this drug alone. GSK's consensus analyst rating is 'hold' with a mean price target of ~$58 (8.5% implied upside from ~$51.60).

How It Works

Cabotegravir is an integrase strand transfer inhibitor (INSTI), it blocks an enzyme HIV needs to replicate. Apretude is formulated as a long-acting injection that releases the drug slowly over months, so patients receive a starting dose, another dose one month later, and then an injection every two months to maintain protection against HIV infection.

Trial Status

Apretude received FDA approval in December 2021 based on two pivotal Phase 3 trials (HPTN 083 and HPTN 084) showing superior efficacy to daily oral TDF/FTC in cisgender men/transgender women who have sex with men (p=0.0003) and in cisgender women (p<0.0001). Multiple real-world implementation studies presented at IDWeek 2024 and CROI 2025 demonstrate >99% effectiveness with zero HIV acquisitions in varied clinical settings.

The Two-Sided Case

▲ Bull Case4
First and only long-acting injectable for HIV PrEP, a clear differentiation from daily oral pills (Truvada/Descovy), addressing adherence challenges
Real-world data showing >99% effectiveness and zero HIV acquisitions in implementation studies (CROI 2025) supports clinical and payer confidence
Approved in 50+ countries with positive NICE recommendation for NHS access in England and Wales (Oct 2025), expanding the addressable market
Six doses per year dosing schedule vs. 365 daily pills creates a strong adherence and convenience value proposition
▼ Bear Case4
Gilead's lenacapavir (Sunlenca), a twice-yearly injectable, is emerging as a potential competitive threat for PrEP, if approved, it would offer even less frequent dosing than Apretude's every-2-month schedule
As a branded specialty drug, Apretude faces payer access and reimbursement hurdles; generic oral PrEP options already exist at lower cost
GSK is a large, diversified pharma (consensus rating 'hold'), so Apretude's individual contribution is diluted across a massive pipeline, even material Apretude news is unlikely to move GSK stock significantly
Long-acting injectable requires healthcare-provider administration, creating a logistical barrier vs. widely available oral pills

Upcoming Catalysts

  • Quarterly GSK earnings reports with ViiV/Apretude sales disclosures
  • Potential FDA or EMA label expansions (e.g., broader age groups or dosing intervals)
  • Competitive landscape updates from Gilead's lenacapavir PrEP program
  • Pricing/reimbursement decisions in additional countries

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 7

Hover a chip for the title
1 gsk.com2 gsk.com3 us.gsk.com4 us.gsk.com5 viivhealthcare.com6 apretude.com7 drugs.com